NFlection Therapeutics

Development of  therapies for Neurofibromatosis 1

Also Clin0 congenital birthmarks, RD/Clin0 squamous cell carcinoma

NFlection Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel topical treatments for rare dermatological disorders that involve dysfunction in the RAS pathway. RAS proteins play a crucial role in cell growth and signaling. NFlection utilizes mitogen-activated protein kinase kinase (MEK) inhibitors to target a key protein in the RAS signaling pathway in order to halt the growth of abnormal cells. Formulating these inhibitors as topical gels allows for convenient and localized treatment, circumventing systemic side effects that come with oral or injectable drugs. These topical treatments could help patients with neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks.